RA Capital Management »

Sab Biotherapeutics shares owned by RA Capital Management

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by RA Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $8.8M 4.4M 2.01
2023-12-31 $1.6M 2.4M 0.69

More positions owned by RA Capital Management

Ascendis Pharma A/s - SH (ASND)
Rhythm Pharmaceuticals SH (RYTM)
Vaxcyte SH (PCVX)
Avidity Biosciences SH (RNA)
Cidara Therapeutics SH (CDTX)
Sionna Therapeutics SH (SION)
89bio SH (ETNB)
Newamsterdam Pharma Co Nv SH (NAMS)
Mineralys Therapeutics SH (MLYS)
Janux Therapeutics SH (JANX)
Arcellx SH (ACLX)
Lenz Therapeutics SH (LENZ)
Tyra Biosciences SH (TYRA)
Edgewise Therapeutics SH (EWTX)
Wave Life Sciences SH (WVE)

View all positions for RA Capital Management

Top funds holding Sab Biotherapeutics

Vivo Capital
RA Capital Management
Commodore Capital
Woodline Partners
Sessa Capital IM
BVF
Sphera Funds Management
Vanguard Group
HB Wealth Management
AWM Investment Company
Geode Capital Management
Renaissance Technologies
Pathstone Holdings
Virtu Financial
Kovitz Investment Group Partners

View all funds holding Sab Biotherapeutics